What's fueling PRAX stock's jaw-dropping 235% surge on Thursday?

Core Insights - Praxis Precision Medicines experienced a significant stock increase of 235% following the announcement of positive topline results from two pivotal Phase 3 studies of ulixacaltamide for essential tremor [1] Company Summary - The company reported successful outcomes from its Phase 3 clinical trials, which are critical for the development of ulixacaltamide as a treatment for essential tremor [1] - The positive results are expected to enhance the company's market position and investor confidence, leading to a substantial rise in stock value [1]